– Interview with José María Fernández Sousa-Faro, Ph.D., President of the Spanish Association of Bioenterprises (ASEBIO), and Chairman of the Zeltia Group

Previous articleHopes Dashed for Alzheimer’s Patients
Next articleApproved Immunosuppressant Found to Be Effective in Mouse Model of Alzheimer Disease